After being treated for bladder pain syndrome with pentosan polysulfate sodium (sold under the brand name Elmiron) for two years, a woman in Texas says she experienced progressive vision problems that eventually led to blindness.
According to court filings, the patient began taking Elmiron in 1997 and less than two years later began to experience blurred vision and having trouble with her eyes adjusting in dim lighting. In 2002, she was diagnosed with maculopathy. Additional medical notes showed that pigment changes were also present on the macula of both eyes.
Unfortunately, in 2010, doctors determined the patient was legally blind from macular degeneration and in 2013, she was further diagnosed the eye disease pigmentary retina dystrophy, which is typically characterized by colored spots on the retina.
Elmiron Research Warns of Potential Eye Damage Complications
The patient and her physicians did not know that Elmiron could cause vision damage, as there were no warnings indicating adverse vision events and the first major study connecting the bladder pain drug to vision damage wasn’t published until 2018.
In that study, published in 2018 in the Journal of Urology physicians from the Emery Eye Center noted eye damage and vision problems in six patients who had been treated with Elmiron. More studies followed regarding the association between eye damage and use of Elmiron.
Elmiron Warning Label Changes Delayed in the U.S.
In 2019, the European Medicines Agency required Elmiron maker Janssen to update the label to warn of the potential for eye damage. Health Canada required the same warning label update later the same year. However, it wasn’t until June 2020 that Janssen updated the U.S. warning label to alert the medical community that pigmentary maculopathy had been identified in Elmiron patients.
In October 2020, the Texas patient was diagnosed by a retinal specialist with chorioretinal degeneration and noted significant pigment changes to the retinal tissue and diffuse outer retina atrophy, elements of Elmiron toxicity.
The patient and her husband are seeking damages for the serious injuries the wife allegedly suffered due to use of Elmiron. The claim was filed in the U.S. District Court for the Eastern District of Pennsylvania.
Elmiron Linked to Vision Damage
New studies indicate that the drug Elmiron, a medication already linked to health issues, may also cause vision problems in women with long-term use. The medication is often prescribed as treatment for urinary tract infections as well as osteoarthritis and other conditions.
Studies on Eye Damage
Several studies have been done on the side effects of Elmiron with more investigations underway. Information links Elmiron and vision damage. The amount of damage correlates with the quantity of the medication taken.
Elmiron was approved by the US Food and Drug Administration (FDA) to treat interstitial cystitis, which is a chronic condition of the bladder. It can cause pressure in the bladder along with pain. With long-term use, research indicates that it may be possible for Elmiron to cause pigmentary maculopathy.
This condition impacts the part of the retina known as the macula, which is the central part of the eye. It can cause issues with changes to light. The job of the macula is to protect the retina from UV light, which allows the person to see details better.
The Emory Eye Center, based in Atlanta, GA, made a report that showed that patients who had been taking the drug for about 15 years had changes in their macula. Another 10 patients had a diagnosis of interstitial cystitis and had been prescribed Elmiron. They also showed symptoms that corresponded with pigmentary maculopathy.
Another study was done by Kaiser Permanente which showed that about 24 percent of patients who had been prescribed Elmiron for a minimum of five years had damage to the eye.
Signs of Damage to the Eye
Symptoms associated with this condition include the following:
- Vision loss
- Difficulty with reading
- Vision that is distorted
While the condition can be preventable, it may not be treatable if it develops. This condition is just the latest to be related to Elmiron. Other conditions include the following:
- Optic neuritis and
- Retinal hemorrhage
Even after the patient discontinues the mediation, damage may occur. They may have difficulty adapting to an environment with low lighting. The condition can mimic macular degeneration in its later stages.
Anyone experiencing these symptoms after taking Elmiron should talk to their doctor about treatment. While it is never advised to stop taking prescription medication without consulting with their doctor first, it is important to arrange an appointment to discuss their symptoms with a medical professional right away. If they have taken Elmiron in the past and are experiencing vision changes, they will want to present that information to their doctor.
As the only FDA-approved treatment for IC, it must be continually taken, which means that thousands of patients may have been using Elmiron for years or even decades without knowing about the potential for vision damage. Even with the studies being conducted, Janssen Pharmaceuticals failed to warn the public until regulatory agencies applied pressure. Even when warnings were required in Europe and Canada, no changes were made to the labels in the US until June 2020. It is expected that more people will come forward with evidence of vision damage as the public becomes aware of the situation.
Changes in Priority List for COVID-19 Vaccine
Supplies for the COVID-19 have been limited in California. At this time, only health care workers, staff and residents in long-term care facilities have been getting it as well as people who are age 65 and older. However, the list for who may be top priority in the future could be changing in the state.
Governor Gavin Newsom has announced who will be top priority for the next phase of vaccination. The plan is to switch to an approach based on age. This is a change from the earlier tier plan where workers who were in commercial and residential settings as well as those who were in transportation and manufacturing would be the next priority. It also included homeless people and those who are incarcerated.
No details about how the groups would be divided by age have been given. Some speculate that it may start with those age 50 and up. Many groups have pushed to have these changes made. However, there are other groups who don’t support the age-based approach. Labor unions are critical because they say essential workers should be protected by getting access to the vaccine right away since they are put at risk for doing their jobs.
Groups that support people with disabilities say that those who are at highest risk aren’t being prioritized. The changes don’t consider those who have the most risk for complications with the virus.
When Vaccinations Will Occur
California state officials have indicated that it may be June before everyone who is 65 and older have been able to get the vaccine. The state is getting about 300,000 to 500,000 doses per week. For Los Angeles County, that many doses would be needed each week just to get the adult residents vaccinated by the middle of summer. It is expected that it will be mid-2022 before everyone is vaccinated.
When it comes to priority by industry, healthcare workers are the top priority. Teachers come next because they are the key to getting schools open again for in-person learning. After teachers, it is workers based in the food and agriculture industries with those in emergency services coming next. There is no current timeline for when those workers are able to sign up for vaccinations.
Vaccinations are going slow in part because a significant portion are going to people getting their second dose. That takes away from those who are seeking their first dose. Adding to the complications is the weather. In Orange County, strong winds caused the Disneyland vaccine site to close, which made thousands of people have to reschedule.
Right now, residents age 65 and older are able to sign up for appointments for vaccination in the state. The goal for Orange County is to get all residents their vaccinations by July 4th. Ventura County is allowing residents age 75 and older to sign up for the vaccine. Other counties have their own restrictions for the vaccine and vaccination sites set up for administration based on the number of doses they receive.
FDA Adds Nearly Two Dozen Drugs to Watch List
The US Food and Drug Administration (FDA) has released a new watch list for drugs and classes of drugs. They have included almost two dozen products which may have a serious risk for side effects or new safety information has been discovered.
New Drugs to Watch For
The drugs on the list aren’t necessarily a risk for patients, but the agency believes there may be a potential problem. Further review is necessary at which point the FDA can decide to take action. These actions include:
- Require changes to the label
- Restrict use of the drug
- Remove the drug from the market
Several proton pump inhibitors were included in the list. Multiple risks were identified for this class of drug. One group had 10 different drugs that could increase the risk for SIADH or syndrome of inappropriate antidiuretic hormone secretion.
Hydroxychloroquine sulfate has received a lot of media attention lately in connection to its use in treating COVID-19. The FDA listed products that contain the ingredient because it may carry a risk for phospholipidosis. This is a condition where phospholipids build up in the tissues of the system. There is concern in patients with this condition that their liver and kidneys are functioning properly.
Also on the list is Eucrisa, otherwise known as crisaborole. This drug is used to treat mild to moderate eczema, but it may carry a risk for developing contact dermatitis. The labeling for the drug was updated to indicate this possibility.
Lipiodol was on the list for the risk of hypothyroidism, and the FDA is currently evaluating the possibility of more action. Another area of concern is with vascular endothelial grown factor inhibitors. VEGF inhibitors include Avastin, Caprelsa, Cometriq, Lenvima, and many others. They may have an increased risk for the patient to develop an aneurysm or artery dissection. The FDA is currently determining the need for regulatory action on this class of drugs.
Aimovig is another drug on the list, which may increase the risk for hypertension. This medication is used in the treatment for migraines because it can prevent the activation of a specific protein that may lead to the headache.
Belsomra may lead to falls, resulting in serious injuries. This drug has been updated with labeling that indicates the increased risk for falls. This medication is prescribed by doctors to treat insomnia.
Impavido may lead to eye disorders. It is used to treat parasites. Vasostrict, which is used to treat diabetes insipidus, may actually increase the risk of the disease. The label for this drug was updated to indicate the issue.
While these drugs haven’t been proven to cause harm to the patient, they do carry the potential for risk. Anyone who is taking these medications can talk to their doctor about the concerns they may have. The doctor may alleviate their fears or prescribe an alternative treatment. They can also stay updated by visiting the FDA website to learn about any further research or action being taken by the FDA.
Defective Products2 years ago
Dehumidifier Recall: Several Brand Name Humidifiers are Recalled as a Fire Hazard
Medical Devices3 years ago
Complications from Hernia Mesh
Covid-191 year ago
Metformin as Potential Protector from COVID-19
Covid-191 year ago
Moderna Seeks Emergency Approval for COVID Vaccine
Prescription Drugs12 months ago
Recall for Drug Mix-up with Serious Effects
Prescription Drugs1 year ago
Some Heart Meds May Come with Extra Risk
Covid-191 year ago
FDA Adds Nearly Two Dozen Drugs to Watch List
Prescription Drugs1 year ago
Senate Bill May Give More Authority to the FDA for Drug Recall